Welcome to This Week in Clinical Trials. Every Monday, we share the most notable news in clinical trial results — what was tested, what was found, and what it means for patients. This is our edition for Monday, May 25, 2026. First up, a new injectable medicine for COPD lowered yearly flare-ups by about eighteen percent in two big lung studies. Then, a hormone-blocking shot nearly doubled the time before advanced breast cancer started growing again in a Chinese trial. And finally, a new two-in-one blood pressure pill cut the top blood pressure number by about eighteen points. Friendly reminder that you can find plain English summaries of all the latest completed clinical trials at stellatrials.com/learn. Genentech and Roche announced this week that their new drug astegolimab showed promise for people with COPD. COPD is a long-term lung disease that makes breathing harder over time. Quick background. COPD affects more than sixteen million Americans, and it is among the top ten causes of death in the country. It often comes from years of smoking, and it slowly damages the airways. The biggest problem for most patients is something doctors call a flare-up. A flare-up is when COPD symptoms — coughing, mucus, and shortness of breath — suddenly get much worse over a few days. Flare-ups are often set off by a cold, the flu, or bad air quality. The worst ones can land someone in the hospital, and each flare-up tends to leave the lungs a little weaker than before. Today's main treatments are inhalers, but many patients still have flare-ups even with the best inhaler care. The two studies enrolled nearly twenty-seven hundred current and former smokers who had COPD and frequent flare-ups. People got a shot of astegolimab every two or four weeks for a year, on top of their regular inhalers. In the larger phase three study, called ARNASA, the every-four-week shot cut yearly flare-ups by about eighteen percent compared to a dummy shot. In the smaller study, the every-two-week shot lowered flare-ups by about fifteen percent. The other dose schedules trended in the same direction but did not clearly beat the dummy shot. Side effects looked similar between the drug and the dummy shot. Astegolimab is not yet approved. Genentech and Roche say they plan to bring the results to regulators to decide what comes next. The results were published in The Lancet, one of the most respected medical journals in the world. In China, researchers ran a study called FAMILY that tested two different maintenance pills for women with the most common kind of advanced breast cancer. The patients all had hormone-driven, HER-two negative metastatic breast cancer. That is the most common type of breast cancer that has spread, making up about seven in ten advanced cases. The usual playbook is to hit the cancer hard with chemotherapy first. Then doctors switch patients to a gentler long-term medicine — called maintenance therapy — that tries to keep the cancer from coming back. Doctors have argued for years over which maintenance drug works best for this group. The FAMILY trial enrolled two-hundred-ten women across twenty-two hospitals in mainland China. Half got fulvestrant, a hormone-blocking shot. The other half got capecitabine, a mild chemotherapy pill. On fulvestrant, the cancer held off for about seventeen months before it started growing again. On the chemotherapy pill, the cancer started growing again after about nine months. So fulvestrant nearly doubled the time without the cancer getting worse. Serious side effects were also less common in the fulvestrant group. The results were published in Signal Transduction and Targeted Therapy. The trial team says this gives doctors clearer guidance on which maintenance drug works better after first-line chemotherapy in this group of patients. For our last story, we turn to a new pill for high blood pressure. Boryung Pharmaceutical announced this week that their new combination blood pressure pill worked better than one of their older single-drug pills. The new pill blends two blood pressure medicines — fimasartan and indapamide — into a single tablet. For context, almost half of all American adults have high blood pressure. And of those people, only about one in four has it under control. Doctors often need to add a second medicine when one is not enough. But more pills are harder to remember, so a single combination tablet can make staying on treatment easier. The study, called FINEDUO, started with two-hundred-forty-eight patients whose blood pressure was still too high after a month on the older single-drug pill. The researchers split them into two groups. Half were switched to the new combination pill. The other half stayed on the older single drug. Eight weeks later, the patients on the new combination pill saw their top blood pressure number drop by about eighteen points. The patients who stayed on the single drug dropped by only about seven points. Side effects were similar in both groups, even for patients sixty-five and older. Results were published in Drug Design, Development and Therapy. Before we wrap, a shoutout to the American Heart Association. They fund more cardiovascular research than any group outside the federal government, and they offer free CPR training to millions of Americans every year. They're at heart.org. One quick reminder: this show is news, not medical advice. Nothing we cover is meant to replace a conversation with your own doctor about your own care. That's this week in clinical trials. If any of these conditions affect you or someone you love, head to stellatrials.com — you can search for open trials matched to your situation, and follow the progress of trials as results come in. New episode every Monday. See you next week.